Trends in compulsory licensing of pharmaceuticals since the Doha Declaration: a database analysis
about
Biological diversity in the patent system.Compulsory Licenses for Cancer Drugs: Does Circumventing Patent Rights Improve Access to Oncology Medications?Access to drugs for treatment of noncommunicable diseases.Scaling up chronic disease prevention interventions in lower- and middle-income countriesUsing TRIPS flexibilities to facilitate access to medicinesThe Trans-Pacific Partnership: Is It Everything We Feared for Health?Global pharmaceutical regulation: the challenge of integration for developing states.Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis.Should the patent system for pharmaceuticals be replaced? A theoretical approach.ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe.ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of anti-neoplastic medicines in countries outside of Europe.Compulsory licensing of pharmaceuticals reconsidered: Current situation and implications for access to medicines.Individual Responsibility for Promoting Global Health: The Case for a New Kind of Socially Conscious Consumption.Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016.Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C.USMCA (NAFTA 2.0): tightening the constraints on the right to regulate for public health
P2860
Q30392829-0DA4ED1D-9EF7-409A-BE26-0DCB7A52E26DQ33859745-9F78D2C6-A692-45BB-857D-0A66415DFE14Q34916353-023ACD5B-840A-4149-97C6-74648033EB9AQ36939475-D49AFEAA-0D48-4BE5-8F67-B779B7B1C2E7Q36977265-FA5980AB-80FA-4997-9DA2-083351151A14Q37141811-E09D7CEE-B8C9-475F-BADF-F22912A00136Q37522901-09E18E92-331A-4C94-A106-F07FFDE00A45Q37598156-FEDA3D58-1857-4D3E-A921-E0925F1F589EQ38220711-48C7F7C8-E2C8-4273-ABAB-58873E55B1E1Q38908352-D52753F1-C0F4-4F2D-ACCB-89859EBFCF2AQ42693274-749F01C4-4795-4420-8748-AB1C8FF2E300Q46707957-4BA3C43F-8070-4757-BA54-FF6092360289Q47963059-FE25331B-3E0F-42E3-894B-0B8326DB0135Q52659410-AB48E57E-CBC5-4D69-B413-AA2024570501Q53381076-2611C5E2-AB28-41E0-9CDA-F2EB6735F611Q64056021-c717a222-430e-61a2-1b08-f949a8447e75
P2860
Trends in compulsory licensing of pharmaceuticals since the Doha Declaration: a database analysis
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Trends in compulsory licensing ...... claration: a database analysis
@ast
Trends in compulsory licensing ...... claration: a database analysis
@en
Trends in compulsory licensing ...... claration: a database analysis
@nl
type
label
Trends in compulsory licensing ...... claration: a database analysis
@ast
Trends in compulsory licensing ...... claration: a database analysis
@en
Trends in compulsory licensing ...... claration: a database analysis
@nl
prefLabel
Trends in compulsory licensing ...... claration: a database analysis
@ast
Trends in compulsory licensing ...... claration: a database analysis
@en
Trends in compulsory licensing ...... claration: a database analysis
@nl
P2860
P1433
P1476
Trends in compulsory licensing ...... claration: a database analysis
@en
P2093
Reed Beall
P2860
P304
P356
10.1371/JOURNAL.PMED.1001154
P407
P50
P577
2012-01-10T00:00:00Z